Variable growth hormone profiles following withdrawal of long-term 30 mg slow-release lanreotide treatment in acromegalic patients: Clinical implications

European Journal of Endocrinology

Volumn 142, Issue 6, 2000, Pages 565-571

  Caron, Philippe ^a   Tabarin, Antoine ^b   Cogne, Muriel ^a   Chanson, Philippe ^c   Jaquet, Philippe ^d  

^a CHU RANGUEIL   (France)

^b HAUT LÉVÊQUE HOSPITAL   (France)

^c BICÊTRE HOSPITAL   (France)

^d TIMONE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; GROWTH HORMONE;

ACROMEGALY; ADULT; AGED; ARTICLE; CLINICAL TRIAL; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GROWTH HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; SLOW RELEASE FORMULATION;

EID: 0034123755     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1420565     Document Type: Article

References (36)

1. Sassolas G, Harris AG, James-Deidier A & the French SMS 201-995 Acromegaly Study Group. Long-term effect of incremental doses of the somatostatin analog SMS 201-995 in 58 acromegalic patients. Journal of Clinical Endocrinology and Metabolism 1990 71 391-397.
2. Ezzat S, Snyder PJ, Young WF, Boyajy LD, Newman C, Klibanski A et al. Octreotide treatment of acromegaly. A randomized, multicenter study. Annals of Internal Medicine 1992 117 711-718.
3. Plöckinger U, Liehr RM & Quabbe HJ. Octreotide long-term treatment of acromegaly: effect of drug withdrawal on serum growth hormone/insulin-like growth factor-I concentrations and on serum gastrin/24-h intragastric pH values. Journal of Clinical Endocrinology and Metabolism 1993 77 157-162.
4. Caron P, Cogne M, Gusthiot-Joudel B, Wakim S, Catus F & Bayard F. Intramuscular injections of slow-release lanreotide (BIM 23014) in acromegalic patients treated with continuous subcutaneous infusion of octreotide (SMS 201-995). European Journal of Endocrinology 1995 132 320-325.
5. Giusti M, Ciccarelli E, Dallabonzana D, Delitala G, Faglia G, Liuzzi A et al. Clinical results of long-term slow-release lanreotide treatment of acromegaly. European Journal of Clinical Investigation 1997 27 277-284.
6. Frohman LA. Therapeutic options in acromegaly. Journal of Clinical Endocrinology and Metabolism 1991 72 1175-1181.
7. Melmed S, Ho K, Klibanski A, Reichlin S & Thorner M. Recent advances in pathogenesis, diagnosis, and management of acromegaly. Journal of Clinical Endocrinology and Metabolism 1995 80 3395-3402.
8. Barkan AL, Lloyd RV, Chandler WF, Hatfield MK, Gebarski SS, Kelch RP et al. Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate. Journal of Clinical Endocrinology and Metabolism 1988 67 1040-1048.
9. Stevenaert A & Beckers A. Presurgical octreotide: treatment in acromegaly. Metabolism 1996 45 (Suppl 1) 72-74.
10. Colao A, Merola B, Ferone D & Lombardi G. Acromegaly. Extensive personal experience. Journal of Clinical Endocrinology and Metabolism 1997 82 2777-2781.
11. Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ & Ibbertson HK. Determinants of clinical outcome and survival in acromegaly. Clinical Endocrinology 1994 41 95-102.
12. Bates AS, Van't Hoff W, Jones JM & Clayton RN. Does treatment of acromegaly affect life expectancy? Metabolism 1995 44 (Suppl 1) 1-5.
13. Orme SM, McNally RJQ, Cartwright RA & Belchetz PE for the United Kingdom Acromegaly Study Group. Mortality and cancer incidence in acromegaly: a retrospective cohort study. Journal of Clinical Endocrinology and Metabolism 1998 83 2730-2734.
14. Boulle N, Souberbielle JC, Perret MC, Raynaud A & Le Bouc Y. Etude d'une nouvelle trousse de dosage de l'IGF-I. Etablissement des valeurs de référence. Immunoanalyse et Biologie Spécialisée 1997 12 95-98.
15. SAS Institute Inc. SAS/STAT User's Guide, version 6, 4th edition, vol 1-2, Cary, NC: SAS Institute Inc., 1989.
16. Newman CB, Melmed S, George A, Torigan D, Duhaney M, Snyder P et al. Octreotide as primary therapy for acromegaly. Journal of Clinical Endocrinology and Metabolism 1998 83 3034-3040.
17. Lamberts SWJ, van der Lely AJ, de Herder WW & Holland LJ. Octreotide. New England Journal of Medicine 1996 334 246-254.
18. Stewart PM, Stewart SE, Clark PMS & Sheppard MC. Clinical and biochemical response following withdrawal of a long-acting, depot injection form of octreotide (Sandostatin-LAR). Clinical Endocrinology 1999 50 295-299.
19. Harris AG, Prestele H, Herold K & Boerlin V. Long-term efficacy of Sandostatin (SMS 201-995, octreotide) in 178 acromegalic patients. Results from the International Multicentre Acromegaly Study Group. In Sandostatin in the Treatment of Acromegaly, pp 117-125. SWJ Lamberts. Amsterdam: Concensus Round Table. Berlin: Springer. 1987.
20. Ikuyama S, Nawata H, Kato KI, Ibayashi H & Nakagaki H. Plasma growth hormone responses to somatostatin (SRIH) and SRIH receptors in pituitary adenomas in acromegalic patients. Journal of Clinical Endocrinology and Metabolism 1986 62 729-733.
21. Reubi JC & Landolt AM. The growth hormone response to octreotide in acromegaly correlates with adenoma sandostatin receptors. Journal of Clinical Endocrinology and Metabolism 1989 68 844-850.
22. Spada A, Arosio M, Bochicchio D, Bazzoni N, Vallar I, Bassetti M et al. Clinical, biochemical, and morphological correlates in patients bearing growth hormone-secreting pituitary tumors with or without constitutively active adenylyl cylase. Journal of Clinical Endocrinology and Metablolism 1990 71 1421-1426.
23. Adams KF, Lei T, Buchfelder M, Petersen B & Fahlbusch R. Biochemical characteristics of human pituitary somatotropinomas with and without gsp mutations: in vitro cell culture studies. Journal of Clinical Endocrinology and Metabolism 1995 80 2077-2081.
24. Yang I, Park S, Ryu M, Woo J, Kim S, Kim J et al. Characteristics of gsp-positive growth hormone-secreting pituitary tumors in Korean acromegalic patients. European Journal of Endocrinology 1996 134 720-726.
25. Faglia G, Arosio M & Spada A. Gs protein mutations and pituitary tumors: functional correlates and possible therapeutic implications. Metabolism 1996 45 117-119.
26. Barlier A, Gunz G, Zamora AJ, Morange-Ramos I, Figarella-Branger D, Dufour H et al. Prognostic and therapeutic consequences of GS alpha mutations in samatotroph adenomas. Journal of Clinical Endocrinology and Metabolism 1998 83 1604-1610.
27. Kuhn JM, Basin C, Beaudoin C, Emy P, Mollard M, de Rouge B et al. Influence de la dose et des modalités d'administration du BIM 23014 sur la sécrétion d'hormone de croissance de l'acromégale. Annales d'Endocrinologie 1992 53 208-214.
28. Barnard LB, Grantham WG, Lamberton P, d'Orisio TM & Jackson IMD. Treatment of resistant acromegaly with a long-acting somatostatin analogue (SMS 201-995). Annals of Internal Medicine 1986 105 856-861.
29. Tauber JP, Babin T, Tauber MT, Vigoni F, Bonafé A, Ducasse M et al. long-term effects of continuous subcutaneous infusion of the somatostatin analog octreotide in the treatment of acromegaly. Journal of Clinical Endocrinology and Metabolism 1987 68 917-924.
30. Timsit J, Chanson P, Larger E, Duet M, Mosse A, Guillausseau PJ et al. The effect of subcutaneous infusion versus subcutaneous injections of a somatostatin analog (SMS 201-995) on the diurnal GH profile in acromegaly. Acta Endocrinologica 1987 116 108-112.
31. Christensen SE, Weeke J, Orskov H, Moller N, Flyvbjerg A, Harris AG et al. Continuous subcutaneous pump infusion of somatostatin analogue SMS 201-995 versus subcutaneous injection schedule in aeromegalic patients. Clinical Endocrinology 1987 27 297-306.
32. Morange I, de Boisvilliers F, Chanson P, Lucas B, Dewailly D, Catus F et al. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide. Journal of Clinical Endocrinology and Metabolism 1994 79 145-151.
33. Giusti M, Gussoni G, Cuttica CM, Giordano G and the Italian Multicenter Slow Release Lanreotide Study Group. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Journal of Clinical Endocrinology and Metabolism 1996 81 2089-2097.
34. Caron P, Morange-Ramos I, Cogne M & Jaquet P. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. Journal of Clinical Endocrinology and Metabolism 1997 82 18-22.
35. Heron I, Thomas F, Dero M, Gancel A, Ruiz JM, Schatz B et al. Pharmacokineties and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly. Journal of Clinical Endocrinology and 1993 76 721-727.
36. Giusti M, Arosio M, Ciccarell E, Cuttica CM, Dallabonzana D, Delitala G et al. Long-term results with the slow-release formulation of lanreotide in acromegalic patients. Journal of Endocrinological Investigation 1997 20 (Suppl to no 7) 37-42.